New Algorithmic Approach to Address Treatment of Fecal Incontinence

GREENWICH, Conn., Nov. 21, 2011 /PRNewswire/ -- In a new paper published today in Touch Gastroenterology, the researcher addresses the immediate need for a reasoned, stepwise algorithm for treating bowel control disorder (BCD), also known as fecal incontinence (FI). The review evaluates all aspects of the disease state, including some of the newer therapeutic alternatives and outlines the latest treatment algorithm. The review also cites several attempts to determine the true prevalence of this debilitating condition that is estimated to affect tens of millions of people worldwide. BCD has been identified as a common consequence of childbirth and the aging process and the second leading cause of institutionalization in the US.

"Determining what to do and when remains a critical unmet need for clinicians in addressing BCD," said Dr. Mark D. Noar, Director of the Bowel Control Disorder Center at Endoscopic Microsurgery Associates, Towson, MD. "This latest Fecal Incontinence Treatment Algorithm provides the roadmap on critical decision points to be made following unsuccessfully applied conservative methods or pharmacologic therapies."

"This algorithm is a significant advancement that includes all of the newer treatments and clearly outlines all available options for doctors and their patients," said Will Rutan, Mederi Therapeutics' CEO, maker of the Secca Therapy System for BCD. "This decision tree is a valuable tool that also supports the rationale for an alternate course of action, and specifically when Secca may be appropriate as an effective, less complicated and less invasive alternative for BCD."

Additional information is available at Touchgastroenterology.com; November, 2011, at the following link: http://www.touchgastroenterology.com/articles/chronic-faecal-incontinence-review-disease-state-therapeutic-alternatives-and-algorithmic-a and at www.mederitherapeutics.com.

ABOUT SECCA®

Secca therapy is a minimally invasive and effective treatment that bridges the gap between conservative therapies and invasive surgery or implants for bowel control disorder (BCD). Secca involves delivery of radiofrequency energy to the internal anal sphincter, which results in a change in tissue compliance and corresponding improvement in incontinence symptoms. Numerous clinical studies have shown Secca to be a safe and effective therapeutic option. Secca does not preclude next steps with foreign implants or more invasive procedures when indicated.

ABOUT MEDERI

Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics Inc. is located in Greenwich, Connecticut.

Contact: Sheila Doyle, +1-203-930-9980, [email protected]

SOURCE Mederi Therapeutics Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED